Advertisement
YOU ARE HERE: LAT HomeCollectionsSynergen Inc
IN THE NEWS

Synergen Inc

FEATURED ARTICLES
BUSINESS
July 19, 1994 | From Reuters
Synergen Inc. said Monday that its lead product, Antril, has failed in clinical trials for treatment of the blood infection sepsis and that it will cut its staff in half, an announcement that sparked a steep drop in the company's stock price. Synergen's stock lost nearly half its value in heavy trading after the announcement and closed down $4.375 at $4.50 on the Nasdaq, where it was the second-most-active issue in afternoon trading.
ARTICLES BY DATE
BUSINESS
November 19, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Colorado biotechnology company Synergen Inc., once touted as "the next Amgen," will instead be swallowed up by Amgen Inc. in a $239.6-million deal announced Friday. Thousand Oaks-based Amgen said it will pay $9.25 a share for Synergen, one of several high-profile biotech firms battered this year after once-promising drugs flopped in lab tests.
Advertisement
BUSINESS
November 19, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Colorado biotechnology company Synergen Inc., once touted as "the next Amgen," will instead be swallowed up by Amgen Inc. in a $239.6-million deal announced Friday. Thousand Oaks-based Amgen said it will pay $9.25 a share for Synergen, one of several high-profile biotech firms battered this year after once-promising drugs flopped in lab tests.
BUSINESS
July 19, 1994 | From Reuters
Synergen Inc. said Monday that its lead product, Antril, has failed in clinical trials for treatment of the blood infection sepsis and that it will cut its staff in half, an announcement that sparked a steep drop in the company's stock price. Synergen's stock lost nearly half its value in heavy trading after the announcement and closed down $4.375 at $4.50 on the Nasdaq, where it was the second-most-active issue in afternoon trading.
BUSINESS
June 8, 1995 | Times Staff and Wire Reports
Amgen Hires Takeover Specialist as Top Lawyer: The Thousand Oaks-based biotechnology company named George A. Vandeman its senior vice president and general counsel.
CALIFORNIA | LOCAL
September 17, 1990 | Compiled from Times wire and staff reports
Researchers last week began trials in humans of a new form of therapy for rheumatoid arthritis that may block the progression of the disease, which affects 2 million people in the United States. Current therapies for arthritis, such as aspirin, reduce pain and inflammation but do not halt progression of the disease. The researchers, at Synergen Inc. in Boulder, Colo.
BUSINESS
February 2, 1995 | From Times Wire Services
Strong sales of its cancer and kidney drugs helped Amgen Corp. on Wednesday report a 33% jump in profit in the fourth quarter. The profit from operations does not reflect $116 million in costs related to the biotechnology firm's acquisition of Synergen Inc. That write-off depressed net income 95% to $4.8 million, or 3 cents a share, from $91.1 million, or 64 cents a share, in the final three months of 1993.
BUSINESS
January 19, 1993 | From Reuters
Centocor Inc. stopped testing its flagship drug in the United States and suspended sales in Europe on Monday, saying increasing numbers of people have died after receiving the treatment. Once-admiring investors dumped Centocor shares on the NASDAQ market, making it by far the most active stock. The price dropped by $11.375, or nearly two-thirds, to $6.375, with more than 12.7 million shares changing hands.
BUSINESS
November 22, 2001 | BLOOMBERG NEWS
Eli Lilly & Co. won Food and Drug Administration approval of its Xigris drug for severe sepsis, the first treatment approved for the often fatal overreaction to infection. Analysts estimate annual sales for Xigris, a genetically engineered protein, will top $1 billion within a few years of its introduction. Lilly needs new products to make up for declining sales of its Prozac antidepressant, which lost U.S. patent protection in August.
NEWS
January 27, 1990 | THOMAS H. MAUGH II, TIMES SCIENCE WRITER
A new approach to therapy of rheumatoid arthritis and many other diseases--such as diabetes, septic shock and inflammatory bowel disease--may arise from new research reported Thursday in the British journal Nature by a group of Colorado scientists. Molecular biologists from Synergen Inc.
BUSINESS
April 26, 1998
* Tom Reed has been named president of Interplay Films, the new motion picture and television division of Interplay Productions in Irvine. The parent company develops and publishes interactive entertainment software. Reed was formerly vice president at Imagine Entertainment. * James V. Thomas has been appointed president of the Multi-Family Property Management division of Sares-Regis Group in Irvine. He will oversee 9,000 units in California, Colorado, Arizona and Nevada.
BUSINESS
February 9, 1995 | DAVID R. OLMOS, TIMES STAFF WRITER
Shares of Amgen Inc. soared Wednesday before easing off on persistent Wall Street rumors that pharmaceutical giant Bristol-Myers Squibb has takeover designs for the world's largest biotechnology company. Amgen, based in Thousand Oaks, closed up $5.375 at $70.75--a two-year high--in frenzied trading of 6.1 million shares on Nasdaq. Earlier in the day, the stock was up as much as $10.75 at $76.125. Bristol-Myers stock fell $1 to $60.875.
Los Angeles Times Articles
|